Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor

16 Aug 2012

Abstract excerpt

BACKGROUND: The non-receptor tyrosine kinase JAK2 is implicated in a group of myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. JAK2-selective inhibitors are currently being evaluated in clinical trials. Data from drug-resistant chronic myeloid leukemia patients demonstrate that treatment with a small-molecule inhibitor generates resistance via...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Cytokine Signaling Pathways and Interactions
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22916261
DOI: 10.1371/journal.pone.0043437

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase InhibitorPMID 22916261Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.Semantic proximity Read ↗

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.Semantic proximity Read ↗

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.Semantic proximity Read ↗

Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.Semantic proximity Read ↗

The use of structural biology in Janus kinase targeted drug discovery.Semantic proximity Read ↗

Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?Semantic proximity Read ↗

Type II JAK2 Inhibitor CHZ‐868 and HSP90 Inhibitors Are Potent towards the Ruxolitinib Resistant JAK2 Variants in JAK2 Driven Myeloproliferative NeoplasmsSemantic proximity Read ↗

Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.Semantic proximity Read ↗

Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.Semantic proximity Read ↗

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.